Fortress Biotech, Inc. (FBIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.94 |
| Open | 2.01 |
| Day High | 2.01 |
| Day Low | 1.96 |
| 52-Week High | 4.53 |
| 52-Week Low | 1.83 |
| Volume | 183,345 |
| Average Volume | 434,035 |
| Market Cap | 66.37M |
| PE | 0.75 |
| EPS | 2.64 |
| Moving Average 50 Days | 2.44 |
| Moving Average 200 Days | 2.86 |
| Change | 0.05 |
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
GlobeNewswire Inc.
Feb 23, 2026 2:24 PM GMT
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement t
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
GlobeNewswire Inc.
Feb 23, 2026 1:30 PM GMT
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement t
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
GlobeNewswire Inc.
Jan 13, 2026 12:45 PM GMT
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones f